Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well this is completely unexpected. Not complaining but definitely unexpected
164000 at .05 nice buy
I would be careful longhorn, let it be. The guy already said to much in my opinion.
Nice 50000 buy at .05
Not getting excited until we get a update from the horses mouth. Which is only a few weeks away. Maybe sooner if they have really good news. Until then waiting patiently wishing I had more cash to buy more.
Ditto, next question is are they doing phase 2 at the same time or will it be done after the initial animal test.
If they did it at the same time or even if they had to wait, then what are we looking at a completion date end of February first part of March maybe sooner.
Well this just got even more exciting.
Well this puts a possible twist in everyone’s time frame. Which I’m fine with.
The sooner the better. 1st quarter possibility for ide submittal. If his source is reliable.
He does have a point, the doctor never said when the rabbits were delivered.
Guess we will find out when they release the year end and new year plans. Should be putting them out in a couple of weeks
It’ll be interesting to see what comes of this. Hopefully this gives isopet the push it needs
I’m kinda hoping so but at the same time I hope not. My worry is a big pharma will buy them and make it disappear. I know investment wise it will be great for us.
I’m mixed on it, I almost would rather see a partnership and see how successful they will be by turning the cancer industry upside down with radiogel.
Both will be extremely profitable for the share holder one will take Longer than the other.
Guess we will see soon enough.
Isopet will eventually be profitable but it will take some time, they need to get into a big name national vet hospital, like Anderson mentioned. To start becoming profitable sooner.
The clinics here and there will eventually payoff but they will need a lot of them and in my opinion in areas where people have big money into their animals,
Yes it’s something like that, also remember the thyroid is one of the more difficult cancers to treat. So if this gets full approval, it will be a walk in the park to get approval for the easier to treat cancers like skin cancers.
I have no clue what the process would be to get approval on the easier to treat cancers after thyroid gets approved, maybe just a matter of filling out some paperwork. But for some reason I feel a buyout will happen between 2nd &3rd phases of human testing. Hopefully not granted not a bad thing either.
Lol, he’s going by charts when this is strictly a FDA pending approval play to fight cancer. No chart out there is going to tell what will happen and wheat will happen. This is all on news when ide is submitted/approved.
Slight chance isopet could get it to reverse back up to around .10 if they announce some incredible news. It would have to be pretty incredible large contract/partnership possibly. Who knows because unfortunately killing a 1lb tumor isn’t huge news. Sad.
Huuuge winner here. Add more if you can while they are cheap, if not sit back and chill
Slow and steady upward we go, I like it
I thought your 5yr old came up with that
The fda didn’t specify what kind of testing they wanted done in that meeting. Only specific testing. That leaves it wide open for speculation on what they wanted.
It was only last year that the fda told radiogel specifically what kind of testing they would like done.
Nice try though.
Little hints here and there without actually telling us that they are moving forward already.
That’s how I’m reading it. Rabbits are ready to go. It’s all on JHU now
Green on a Monday, good start let’s see what the rest of the week will bring.
Hopefully they will tweet a estimate timeline on the rabbits in the next few days.
This very well could happen maybe on two fronts, one a partnership with isopet and a partnership with radiogel.
Since they are technically separate so why not.
Moderators post the update on the sticky
Not going to lie, I was hoping for a timeline, but regardless still a very good pr.
I appreciate your professional input and your time frames. Much more realistic than anyone else’s especially since most of us have no clue what this all involves.
Don’t waste your time.
Over all a very good pr/update.
Lower shipping costs, extra protection on the product itself.
More patent protections
Rabbits ready to go.
3rd party in place.
Next update should be a time frame, maybe.
Good way to start the year
Sounds like they can start the testing any day now.
Must be pretty good stuff if they are putting out a pr first thing tomorrow morning.
The doctor has always thought there would be a potential buyout before human testing would begin, mainly because a larger company has the funds to easily afford the human testing phases which can be time consuming and very expensive.
Something he said a long time ago is that he would be very open to a buyout.
Time will tell, possibly a buyout if ide is approved
My opinion if a buyout happens it will be between the 2nd and 3rd phases.
Someone woke up on the wrong side of the bed
Actually yes you have said on several occasions that it’s going to .03
Ditto
200000 at .044 nice buys
Vivos Inc Initiates Isopet® Therapy in Horses
Press Release | 06/24/2021
Richland WA, June 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc announced that it has completed the first IsoPet® therapy on an equoid tumor. It was administered at the University of Missouri on a horse that was transported from Ohio. This is an exciting extension of Isopet®, offering an important and unique treatment alternative for larger animals such as horses. The procedure was conducted under mild sedation with a therapy design that, as always, results in no contamination. This first patient is doing well and already the tumor has stopped growing.
Dr. Mike Korenko stated, “Expanding Isopet® into the equine market is an important expansion of the Vivos’ business plan. Treating large tumors in large animals is an area in which IsoPet® is uniquely suited. We intend to further refine the technique with the next few animals and then to collaborate with a private clinic in either Kentucky or Texas.
Owners of potential equine patients are now eligible to complete our new Expression of Interest form specifically for equine therapy under IsoPet Therapy on our web page www.RadioGel.com.”
About Vivos Inc. (OTCQB: RDGL)
Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.
The IsoPet® Solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval is required. Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet® to University animal hospitals and private veterinary clinics.
IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
MKorenko@RadioGel.com
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
MKorenko@RadioGel.com
110000 buy at 42 lucky guy
If the rabbits were just ordered then the cancer cells must be just about ready.
Honestly surprised you got that from him
I agree. I just hope people don’t go on a selling frenzy during the submittal
With what people have posted and including the doctor, about 12 people have 1/6 of the float.
I’m sure there’s other share holders that have more and including us small holders.
I would have to say at least half the shares are locked up in long hands. Possibly closer to 60%.
Ide submittal hits this will go bonkers. Approval even higher depending on how everyone plays their hand.
Lol, tell your friend to lay off of the drugs.
Lol, that’ll work for me
Interesting that the doc bought today, not that I’m complaining it’s definitely a positive sign. Paperwork was done in the same day as well and posted the same day, usually it takes a couple of days before they post the form.
Throwing it out there news tomorrow possibly Monday.